Anti-allergic effect of the new combined nasal spray in experimental allergic rhinitis mode

The aim of the study: to evaluate the anti-allergic properties of the new combined nasal spray in experiment. Materials and methods: the study was performed on 70 male mice of the BALB/c line, which reproduced ovalbumin-induced allergic rhinitis. The animals were immunized for 14 days, after that they provoked acute rhinitis by intranasal administration of ovalbumin. Further, blood sampling was performed in mice with subsequent serum and determination of the concentration of proallergic markers: histamine, IFN-γ, IL-6, IgE and TNF-α by ELISA. The test-spray in doses of 2.5; 5 and 7.5 p/nostril and the reference drugs levocabastine at a dose of 5 p /nostril and beclomethasone in the dose of 3.5 p /nostril was administred intranasally 30 min before provocation of acute allergic rhinitis. Results: when administered to the animals of the test-spray in doses of 2.5, 5 and 7.5 pg/nostril, a decrease in the severity of the allergic reaction in mice with experimental allergic rhinitis was noted, which may be evidenced by a decrease in serum concentrations of histamine, IFN-γ, IL-6, IgE, and TNF-α. At the same time, against the background of intranasal administration of the test-spray at a dose of 5 pg/nostril, the content of histamine, IFN-γ, IL-6, IgE, and TNF-α in serum decreased by 69.1% ((p<0,05); 38.1% ((p<0,05); 130.8% ((p<0,05); 248.2% ((p<0,05); 53.8% ((p<0,05), respectively, which was comparable to the effect of beclomethasone, and exceeded the therapeutic effect of levocabastine. Conclusions: based on the obtained data, assume the equivalent therapeutic efficacy of the test-spray with intranasal glucocorticoids (beclomethasone), which determines the relevance of further study of this composition.

anti-allergic drugs, allergic rhinitis, fexofenadine, ammonium glycirizinate